| Bioactivity | NQTrp, an aromatic naphthoquinone-tryptophan hybrid molecule, an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects. NQTrp inhibits the in vitro aggregation of hexapeptide (41GCWMLY46 within the N-terminus of γD-crystallin) as well as full-length γD-crystallin[1]. |
| Invitro | In TEM analysis, GDC6 peptide fibrils (50 μM) in the presence of NQTrp 5:1, 1:1, 1:5 ratio (GDC6: NQTrp). NQTrp effectively inhibits the fibrillation of the GDC6 peptide (50 μM) in a dose-dependent manner and prevents the formation of elongated amyloid fibrils[1].NQTrp has no toxic effect toward retinal cell culture and reduces the cytotoxicity induced by aggregates of the hexapeptide(IC50=70 μM) in ARPE-19 cells[1]. |
| Name | NQTrp |
| CAS | 185351-19-3 |
| Formula | C21H16N2O4 |
| Molar Mass | 360.36 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Malak Abu-Hussien, et al. An amyloidogenic hexapeptide from the cataract-associated γD-crystallin is a model for the full-length protein and is inhibited by naphthoquinone-tryptophan hybrids. Int J Biol Macromol. 2020 Aug 15;157:424-433. |